Bristol-Myers says panel finds Opdivo lung cancer study meets endpoint

(Reuters) - Bristol-Myers Squibb Co said the independent data monitoring committee concluded that a late stage study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer met its endpoint.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news